CN106478776A - 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途 - Google Patents

抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途 Download PDF

Info

Publication number
CN106478776A
CN106478776A CN201610543024.0A CN201610543024A CN106478776A CN 106478776 A CN106478776 A CN 106478776A CN 201610543024 A CN201610543024 A CN 201610543024A CN 106478776 A CN106478776 A CN 106478776A
Authority
CN
China
Prior art keywords
thr
cell
mice
peptide
bmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610543024.0A
Other languages
English (en)
Chinese (zh)
Inventor
D.博苏康达
P.C.克克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrasos Innovation Inc
Original Assignee
Thrasos Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation Inc filed Critical Thrasos Innovation Inc
Publication of CN106478776A publication Critical patent/CN106478776A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201610543024.0A 2011-07-19 2012-07-19 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途 Pending CN106478776A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161509340P 2011-07-19 2011-07-19
US61/509340 2011-07-19
US201261662337P 2012-06-20 2012-06-20
US61/662337 2012-06-20
CN201280045650.7A CN103890003B (zh) 2011-07-19 2012-07-19 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280045650.7A Division CN103890003B (zh) 2011-07-19 2012-07-19 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途

Publications (1)

Publication Number Publication Date
CN106478776A true CN106478776A (zh) 2017-03-08

Family

ID=47558730

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610543024.0A Pending CN106478776A (zh) 2011-07-19 2012-07-19 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途
CN201280045650.7A Expired - Fee Related CN103890003B (zh) 2011-07-19 2012-07-19 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280045650.7A Expired - Fee Related CN103890003B (zh) 2011-07-19 2012-07-19 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途

Country Status (11)

Country Link
US (2) US20140057831A1 (cg-RX-API-DMAC7.html)
EP (1) EP2734220A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014527040A (cg-RX-API-DMAC7.html)
CN (2) CN106478776A (cg-RX-API-DMAC7.html)
AU (1) AU2012283924A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014001268A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842330A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198333A1 (cg-RX-API-DMAC7.html)
IL (1) IL230510A0 (cg-RX-API-DMAC7.html)
RU (1) RU2014105513A (cg-RX-API-DMAC7.html)
WO (1) WO2013013085A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117653714A (zh) * 2023-03-22 2024-03-08 宁夏医科大学 AAV9-HGF联合TGF-β-Smad受体抑制剂SB431542在治疗矽肺纤维化中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
US20160137714A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
WO2016179106A1 (en) * 2015-05-01 2016-11-10 University Of Miami Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells
CN114181281A (zh) * 2015-05-12 2022-03-15 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
US10844392B2 (en) * 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
ES2906715T3 (es) * 2018-09-06 2022-04-20 Marine Essence Biosciences Corp Of Usa Dispositivos de biomaterial para la regeneración de tejidos guiada
AU2019366366B2 (en) * 2018-10-22 2025-09-25 William D. Carlson Therapeutic combinations of TDFRPs and additional agents and methods of use
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
CN117106029A (zh) * 2020-06-08 2023-11-24 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN113069531B (zh) * 2021-04-09 2023-02-28 南开大学 一种防疤痕皮肤创伤修复用水凝胶及其制备方法
CN116768974A (zh) * 2022-03-11 2023-09-19 中山大学 用于预防和/或治疗肾纤维化的多肽化合物
EP4601667A1 (en) 2022-10-10 2025-08-20 Therapeutics by Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219133A (zh) * 1996-03-22 1999-06-09 通用医疗公司 中枢神经系统局部缺血或损伤后多肽生长因子的给药
WO2007035872A2 (en) * 2005-09-20 2007-03-29 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
US20100015150A1 (en) * 2004-06-17 2010-01-21 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572950B1 (en) * 2002-06-17 2012-10-10 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
US20110275574A1 (en) * 2009-01-16 2011-11-10 Agency For Science, Technology And Research Method of inhibiting proliferation of hepatic stellate cells
US8642834B2 (en) * 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219133A (zh) * 1996-03-22 1999-06-09 通用医疗公司 中枢神经系统局部缺血或损伤后多肽生长因子的给药
US20100015150A1 (en) * 2004-06-17 2010-01-21 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
WO2007035872A2 (en) * 2005-09-20 2007-03-29 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117653714A (zh) * 2023-03-22 2024-03-08 宁夏医科大学 AAV9-HGF联合TGF-β-Smad受体抑制剂SB431542在治疗矽肺纤维化中的应用

Also Published As

Publication number Publication date
WO2013013085A3 (en) 2014-03-13
JP2014527040A (ja) 2014-10-09
US20160058829A1 (en) 2016-03-03
AU2012283924A1 (en) 2014-02-06
HK1198333A1 (zh) 2015-04-02
EP2734220A4 (en) 2015-01-21
CN103890003A (zh) 2014-06-25
CN103890003B (zh) 2016-08-24
CA2842330A1 (en) 2013-01-24
US20140057831A1 (en) 2014-02-27
EP2734220A2 (en) 2014-05-28
IL230510A0 (en) 2014-03-31
WO2013013085A2 (en) 2013-01-24
RU2014105513A (ru) 2015-08-27
BR112014001268A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
JP7696406B2 (ja) 細胞加齢の反転のための一過性細胞リプログラミング
US20140057831A1 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
He et al. Transplantation KCNMA 1 modified bone marrow‐mesenchymal stem cell therapy for diabetes mellitus‐induced erectile dysfunction
EP2976094B1 (en) Methods of treating metabolic disorders
Erickson et al. Meis1 specifies positional information in the retina and tectum to organize the zebrafish visual system
PT2497780E (pt) Compostos relacionados com tdf e seus análogos
JP4652645B2 (ja) Notch経路を用いた組織型または器官型の操作
US20190336575A1 (en) Reversing deficient hedgehog signaling restores deficient skeletal regeneration
CN101300269A (zh) 机械生长因子肽及其用途
US20150147292A1 (en) Novel surface markers for adipose tissue
ES2322881B1 (es) Uso de compuestos agonistas de la actividad pi3k en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de enfermedades neurodegenerativas.
Gurdita Investigating the Mechanisms That Regulate Rod Photoreceptor Positioning and Connectivity in the Developing Murine Retina
Androschuk Methacrylic Acid-Based Biomaterials Promote Terminal Axon Growth
US20230405054A1 (en) Novel nr1 es-derived neural stem cells having a normal karyotype and uses thereof
Griffiths Investigating the Mechanisms of Digit Regeneration and Nerve-Dependency in the Axolotl Limb
KR20260060365A (ko) 골 및 연골 퇴행의 치료를 위한 뇌 유래 골형성 인자 ccn3의 사용 방법
Combs NFATc1 in cardiac valve development and EPDC invasion
Sanchez-Iranzo Characterisation of cardiomyocyte plasticity and the role of fibroblast during zebrafish heart regeneration
JPWO2009044787A1 (ja) テノモジュリンを有効成分とする腱断裂性疾患治療剤
Knight Patterning of the cardiac inflow tract in zebrafish
Saxena Cell Migration and Survival Pathways in Cardiac Development and Disease
JP2011019520A (ja) Notch経路を用いた組織型または器官型の操作
Wang The involvement of JAK2/STAT2/STAT3 in myogenic differentiation
Rishniw Investigation Of Murine Esophageal Myogenesis
Gardner Pathogenic pathways and preclincial testing in mouse models of muscular dystrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170308

WD01 Invention patent application deemed withdrawn after publication